DELFI Diagnostics

Executive Summary

DELFI Diagnostics is a privately held biotechnology company based in Baltimore, MD, founded in 2019, that is pioneering a non-invasive, blood-based early cancer detection platform using its proprietary fragmentomics technology. The company analyzes cell-free DNA (cfDNA) fragmentation patterns through advanced next-generation sequencing and machine learning to identify cancer-specific signatures. Its lead product, FirstLook Lung, is designed for early detection of lung cancer and is currently being evaluated in the large-scale CASCADE-LUNG clinical trial. DELFI's approach has the potential to significantly improve cancer screening rates by offering a simple blood test that could complement or replace existing imaging-based methods. While the company remains private and has not disclosed funding details, its technology has garnered attention for its novel application of cfDNA biology. The key near-term value driver is the completion and data readout from the CASCADE-LUNG trial, which could support regulatory submission and commercialization. DELFI's success hinges on demonstrating clinical validity and utility in large, diverse populations, which is critical for payer coverage and guideline inclusion. Given the strong unmet need for accessible lung cancer screening and the promising preliminary data, DELFI represents a compelling high-risk/high-reward opportunity within the liquid biopsy space.

Upcoming Catalysts (preview)

• Q3 2026CASCADE-LUNG Trial Data Readout70% success
• Q4 2026FDA Submission for FirstLook Lung60% success
• Q2 2026New Clinical Collaboration or Partnership50% success